Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Goldman Sachs Group Inc Acquires 500,000 Shares

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Goldman Sachs Group Inc purchased 500,000 shares of Attovia Therapeutics stock in a transaction dated Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $8,500,000.00. Following the completion of the acquisition, the insider owned 3,020,632 shares of the company’s stock, valued at approximately $51,350,744. This trade represents a 19.84% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Goldman Sachs Group Inc also recently made the following trade(s):

• On Wednesday, August 5th, Goldman Sachs Group Inc sold 105,807 shares of Attovia Therapeutics stock. The shares were sold at an average price of $21.28, for a total value of $2,251,572.96.
• On Wednesday, August 5th, Goldman Sachs Group Inc acquired 85,000 shares of Attovia Therapeutics stock. The shares were acquired at an average price of $21.00 per share, with a total value of $1,785,000.00.

Attovia Therapeutics Trading Up 6.2%

Shares of Attovia Therapeutics stock opened at $19.18 on Friday. Attovia Therapeutics, Inc. has a 52 week low of $16.15 and a 52 week high of $22.79.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. lifted its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.